Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06919081
PHASE2

Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

Sponsor: University of Illinois at Chicago

View on ClinicalTrials.gov

Summary

In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical mesenchymal stem cell secretome or vehicle, with continued follow-up for up to Day 70.

Official title: Phase II Study of the Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2025-08-01

Completion Date

2026-06-15

Last Updated

2026-01-29

Healthy Volunteers

No

Interventions

DRUG

Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome

Eye Drops

OTHER

Vehicle Control

Eye Drops

Locations (1)

University of Illinois at Chicago

Chicago, Illinois, United States